Background
==========

Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neoplasms with multiple clinical characteristics. PNETs are considered more indolent tumors and are associated with better long-term survival rates than with tumors of the exocrine pancreas \[[@b1-medscimonit-23-5574]--[@b3-medscimonit-23-5574]\]. PNETs account for approximately 1--2% of all pancreatic neoplasms and 7.0% of all neuroendocrine tumors \[[@b4-medscimonit-23-5574]\]. The annual incidence of PNETs in the United States is estimated to range between 2 and 5 cases per one million individuals but appears to be rising \[[@b5-medscimonit-23-5574]\]. PNETs can be classified as either functional or nonfunctional. The majority (60%--90%) of PNETs are nonfunctional. Complete surgical resection of a PNET has been suggested to be the only potentially curative treatment for the disease, similar to pancreatic adenocarcinoma \[[@b6-medscimonit-23-5574]\]. PNETs have a better prognosis than pancreatic ductal adenocarcinoma (PDAC). The 5-year survival rate after radical resection is approximately 86.4% \[[@b7-medscimonit-23-5574]\]. Several studies have found that many host-related factors affect survival in PNETs. Intrinsic tumor characteristics, such as tumor sizes, stages, and grades; Ki-67 indices; and lymph node involvement, have long been shown to be associated with clinical outcomes \[[@b8-medscimonit-23-5574]--[@b10-medscimonit-23-5574]\]. Other clinical and pathologic factors used to predict disease progression include patient age at diagnosis, visceral pleural invasion status, and margin status \[[@b11-medscimonit-23-5574]\]. Information regarding these factors is generally useful, but most of these factors are determined only after surgery. Therefore, it is necessary to search for potential prognostic indicators that are available before surgery.

Increasing evidence suggests that inflammatory cells are an essential component of the tumor microenvironment and play a role in tumor progression \[[@b12-medscimonit-23-5574]--[@b15-medscimonit-23-5574]\]. Inflammatory chemokines, including neutrophil-attracting cysteine-X-cysteine chemokines, can either be triggered by the tumor itself or be part of the host innate response to the cancer. Markers of systemic inflammation, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), are generally appealing to clinicians, as these laboratory data are routinely collected prior to surgery and are therefore readily available. The NLR and PLR have been identified as prognostic factors. Elevated NLR and PLR have been shown to be correlated with advanced stages and poor prognoses in a variety of human tumors, including colorectal cancer \[[@b16-medscimonit-23-5574]\], hepatocellular carcinoma \[[@b17-medscimonit-23-5574]\], breast cancer \[[@b18-medscimonit-23-5574]\], gastric neuroendocrine tumors \[[@b19-medscimonit-23-5574]\], and pancreatic cancer \[[@b20-medscimonit-23-5574]\]. However, the roles of NLR and PLR and the clinical significance of these parameters in PNETs remain under evaluation. The goal of this study was to assess the prognostic value of the NLR and PLR in patients with PNETs following potentially curative resection. Further, we compared the discriminative ability of the NLR with other inflammation-based scores to determine whether the NLR is a useful marker for predicting patient outcomes. Additionally, we refined the existing stratification systems by incorporating the NLR into the existing TNM staging system or WHO classification.

Material and Methods
====================

Study population
----------------

Patients who underwent surgical resection for PNETs from November 2003 to August 2016 at the First Affiliated Hospital, Zhejiang University School of Medicine, were retrospectively reviewed. The diagnosis of PNET was made based on standard histologic criteria. The TNM stage of each PNET was determined based on the American Joint Committee on Cancer TNM Classification, while the grade of each PNET was determined according to the 2010 WHO classification of NETs of the GEP system. Patients were excluded if they: (1) showed clinical evidence of infection or evidence of hyperpyrexia at the time of diagnosis; (2) were treated for recurrent disease; (3) received preoperative radiochemotherapy prior to surgery; (4) had a history of cancer of any type; or (5) did not consent to the use of their medical records for research purposes. We included only those patients who had survived for at least 60 days after surgery to exclude perioperative mortality-related bias. All patients underwent potentially curative resection. Finally, 172 patients with PNETs were included ([Figure 1](#f1-medscimonit-23-5574){ref-type="fig"}). We also enrolled 172 healthy volunteers with similar age and sex distributions from the physical examination center in our hospital. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count, while the lymphocyte-to-monocyte ratio (LMR) was calculated by dividing the absolute lymphocyte count by the absolute monocyte count on preoperative routine blood tests. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine.

Follow-up
---------

Patient follow-up was performed by reviewing hospital records or contacting patient family members. Overall survival (OS) was defined as the time span extending from the date of initial diagnosis until the date of death from any cause or the date of last known contact. Disease-free survival (DFS) was defined as the time extending from the date of surgery to the date of PNET recurrence. Patients who did not have evidence of local recurrence or metastasis at the last follow-up and patients who had died of diseases unrelated to PNETs were censored in the analysis of DFS. Our department follows up with patients every 6 months for the first 5 years after surgery and then yearly thereafter. The following postoperative follow-up data were collected for each patient: clinical symptoms and signs, laboratory test results, and radiological examination results. Once recurrence was confirmed, patients were treated by repeat tumor resection, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), systemic chemotherapy, and somatostatin analogue therapy, according to the sizes, numbers, and locations of their recurrent tumors.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL, USA) for Windows. Differences in the NLR and PLR between patients and healthy subjects were evaluated by *t* tests in the case of normally distributed variables or by the Mann-Whitney U test in the case of abnormally distributed variables. Area under the curve (AUC) values obtained from the receiver operating characteristic (ROC) curve analysis were used to compare the predictive efficacies of the NLR and other inflammation-based scores. The associations between NLR and PLR and other prognostic factors were analyzed using chi-square and Fisher exact tests. The Kaplan-Meier method and the log-rank test were used to calculate OS and DFS. Prognostic analysis was performed using univariate and multivariate Cox regressions models. A p value \<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 172 patients with histologically confirmed PNETs were included in the present analysis. These patients were diagnosed at a mean age of 52.92±12.55 years and were evaluated over a mean follow-up period of 48.04±35.2 months. Seventy-three (42.4%) of these patients had grade 1 disease, 76 (44.2%) had grade 2 disease, and the remaining 23 (13.4%) had grade 3 disease. The majority of patients (150/172, 87.2%) had stage I or II disease. A total of 166 patients underwent curative resections (R0 resection, 96.5%), while palliative surgery (R1 resection, 3.5%) was performed for only 6 patients. The operative procedures included the distal pancreatectomy (n=89), pancreaticoduodenectomy (n=53), enucleation (n=23), middle pancreatectomy (n=4), and total pancreatectomy (n=3). The pathology showed lymph node metastasis in 33 (19.2%) patients. At the time of the last follow-up visit, 46 patients had relapsed and 28 patients had died. The 1-, 3- and 5-y OS rates for the entire cohort were 98%, 90% and 78%, respectively, and the 1-, 3- and 5-y DFS rates for the entire cohort were 84%, 72%, and 71%, respectively.

Blood NLRs and PLRs were elevated in patients with PNETs
--------------------------------------------------------

As shown in [Table 1](#t1-medscimonit-23-5574){ref-type="table"}, platelet counts and lymphocyte counts were significantly lower in the blood of patients with PNETs than in the blood of normal volunteers (NVs) (both p\<0.05). The PLR, NLR, and neutrophil counts were significantly higher in the patients with PNETs than in NVs (all p\<0.05).

Correlations between the NLR and PLR and other PNET clinical parameters
-----------------------------------------------------------------------

Baseline patient demographic and clinicopathologic characteristics, which were stratified by NLR and PLR, are summarized in [Table 2](#t2-medscimonit-23-5574){ref-type="table"}. Preoperatively, the NLR was \>2.31 in 67 (39.0%) patients, while the PLR was \>153.4 in 50 (29.1%) patients. Univariate analysis revealed that an increased NLR and PLR were both associated with advanced AJCC stage, high grade, high alkaline phosphatase (AKT) level, and R1 resection (all p\<0.05). Additionally, elevated NLR was associated with the presence of vascular lymph node invasion (LVSI) (p=0.027) and perineural invasion (p=0.038). In contrast, an elevated PLR was associated with tumor location (p=0.048).

Prognostic significance of variables and cut-off value determination
--------------------------------------------------------------------

The results of the univariate survival analysis for each of the clinicopathologic variables are shown in [Tables 3](#t3-medscimonit-23-5574){ref-type="table"} and [4](#t4-medscimonit-23-5574){ref-type="table"}. Both a high NLR and a high PLR were significantly associated with a poor prognosis. Patients with a high NLR or PLR had shorter OS (HR=4.907, 95% CI 2.048--11.756, p\<0.001 and HR=3.307, 95% CI 1.499--7.297, p=0.003, respectively) and DFS (HR=4.143, 95% CI 2.229--7.701, p\<0.001 and HR=2.617, 95% CI 1.465--4.675, p=0.001, respectively) than patients with a low NLR or PLR ([Figure 2](#f2-medscimonit-23-5574){ref-type="fig"}). Furthermore, high tumor grade, presence of LVSI and perineural invasion, large tumor, high stage, increased AKT level, high LMR, nonfunctional tumor, and symptomatic tumor were prognostic factors for poor OS (p\<0.05 for all). High grade, presence of LVSI and perineural invasion, large tumor, high stage, increased AKT level, high LMR, nonfunctional tumor, and male sex were associated with poor DFS (p\<0.05 for all).

In multivariate analysis, NLR remained significantly associated with OS (HR=4.471, 95% CI 1.531--13.054, p=0.006) and DFS (HR=2.531, 95% CI 1.202--5.329, p=0.015) ([Tables 3](#t3-medscimonit-23-5574){ref-type="table"}, [4](#t4-medscimonit-23-5574){ref-type="table"}). Furthermore, WHO grade, AJCC stage, perineural invasion, and radical resection were independent predictive factors for OS (p\<0.05 for all measurements, [Table 3](#t3-medscimonit-23-5574){ref-type="table"}), whereas WHO grade, AJCC stage, and perineural invasion were independent predictive factors for DFS (p\<0.05 for all, [Table 4](#t4-medscimonit-23-5574){ref-type="table"}).

ROC curve analysis showed that the AUCs of the NLR, PLR, LMR, and tumor size were 0.785, 0.67, 0.747, and 0.709, respectively, and that the best cut-off values for the above parameters were 2.31, 151.4, 3.22, and 3.5, respectively, as these values were both the most sensitive and the most specific in predicting survival ([Figure 3](#f3-medscimonit-23-5574){ref-type="fig"}).

Subgroup analyses of the parameters associated with the NLR
-----------------------------------------------------------

We investigated the prognostic value of the NLR relative to AJCC stage, grade, age, sex, LVSI, tumor size, and perineural invasion ([Table 5](#t5-medscimonit-23-5574){ref-type="table"}). We noted a strong association between NLR and OS, which was independent of AJCC stage (p=0.002 for stage I/II; p=0.041 for stage III/IV), tumor size (tumor size ≤3.5 cm, p=0.016; tumor size \>3.5 cm, p=0.006), and sex (male, p=0.021; female, p=0.007). We also noted a strong association between NLR and DFS, which was independent of age (age ≤56, p=0.017; age \>56, p\<0.001), tumor size (tumor size ≤3.5 cm, p=0.002; tumor size \>3.5 cm, p=0.007), and sex (male, p=0.005; female, p=0.003). Furthermore, a high NLR was significantly associated with shorter OS in older (\>56 y) ([Figure 4A](#f4-medscimonit-23-5574){ref-type="fig"}) patients with low-grade tumors (1 and 2) ([Figure 4B](#f4-medscimonit-23-5574){ref-type="fig"}), patients with tumors without perineural invasion ([Figure 4C](#f4-medscimonit-23-5574){ref-type="fig"}), and patients with tumors without LVSI ([Figure 4D](#f4-medscimonit-23-5574){ref-type="fig"}). Moreover, a high NLR was associated with poor DFS in patients with stage I/II disease ([Figure 5A](#f5-medscimonit-23-5574){ref-type="fig"}), patients with low-grade tumors ([Figure 5B](#f5-medscimonit-23-5574){ref-type="fig"}), patients with tumors without perineural invasion ([Figure 5C](#f5-medscimonit-23-5574){ref-type="fig"}), and patients with tumors without LVSI ([Figure 5D](#f5-medscimonit-23-5574){ref-type="fig"}) (p\<0.01 for all measurements).

Comparative performance of the NLR and other predictive models
--------------------------------------------------------------

To further evaluate the prognostic values of the NLR, other inflammation-based scores and the conventional stratification systems, an ROC analysis was performed and the AUC values were compared. The NLR had a higher AUC value (0.736; p\<0.001) than the PLR and LMR ([Figure 6A](#f6-medscimonit-23-5574){ref-type="fig"}). However, the conventional staging systems were superior to the inflammation-based scores in the OS prediction for PNETs ([Table 6](#t6-medscimonit-23-5574){ref-type="table"}). In addition, the predictive ability of the AJCC staging system was superior to that of the WHO classification in our cohort (AUC value: 0.846 *vs.* 0.784).

The model integrating the NLR and the AJCC stage for OS prediction had higher AUC values than that of the AJCC stage alone (0.916 *vs.* 0.846), while the predictive abilities of the model integrating the NLR and the WHO classification was superior to that of the WHO classification alone (0.857 *vs.* 0.784) ([Figure 6B](#f6-medscimonit-23-5574){ref-type="fig"}).

Discussion
==========

The results of the present study showed that the preoperative NLR, but not the PLR, was an independent risk factor for OS (HR=4.471, 95% CI 1.531--13.054, p=0.006) and DFS (HR=2.531, 95% CI 1.202--5.329, p=0.015) in PNET patients undergoing potentially curative resection. Furthermore, we observed that elevated preoperative NLR and PLR were both associated with advanced tumor stages and higher tumor grades. Finally, we showed that the NLR outperformed other inflammation-based scores in terms of its discriminatory capacity. The predictive models incorporating the NLR and conventional stratification systems, including the WHO classification and AJCC stage, showed improved predictive power relative to those of the stratification systems alone.

Increasing evidence has confirmed that systemic inflammation is associated with poorer cancer-specific survival in patients with different types of cancer \[[@b21-medscimonit-23-5574]--[@b24-medscimonit-23-5574]\]. Among several prognostic scores, the NLR, the PLR, the Glasgow prognostic score (GPS) based on serum C-reactive protein (CRP) and albumin, the prognostic index (PI) based on CRP and WBC counts, and the prognostic nutritional index (PNI) based on albumin and lymphocyte count are recognized as useful for predicting outcomes after surgery in specific host subgroups \[[@b25-medscimonit-23-5574],[@b26-medscimonit-23-5574]\]. More recently, the NLR, which can comprehensively reflect inflammatory and immune status in patients with cancer, has been shown to be a reliable marker for predicting the survival of patients with different types of cancer, such as lung cancer \[[@b27-medscimonit-23-5574]\], colorectal cancer \[[@b21-medscimonit-23-5574]\], liver cancer \[[@b17-medscimonit-23-5574]\], breast cancer \[[@b18-medscimonit-23-5574]\], PDAC \[[@b20-medscimonit-23-5574]\], and renal cell carcinoma \[[@b22-medscimonit-23-5574]\]. In addition, many studies have confirmed that the PLR is a marker of patient immune status and long-term survival. PLR is also a prognostic marker in several different tumor types \[[@b28-medscimonit-23-5574],[@b29-medscimonit-23-5574]\]. However, Shirai et al. reported that an increased preoperative PLR was not associated with OS in patients undergoing elective pancreatic resection \[[@b30-medscimonit-23-5574]\]. Another study reported that the PLR has no prognostic value in oesophageal cancer \[[@b31-medscimonit-23-5574]\]. The heterogeneity across these studies may be attributed to several factors, such as differences in PLR cut-off values, differences in inclusion and exclusion criteria, differences in statistical analysis methodologies (univariate *vs.* multivariate analyses, differences in the covariates investigated in the multivariate analysis), and differences in treatment schedules. Regarding NETs, the report by Salman et al. revealed that elevated NLR and PLR were associated with a high tumor grade and advanced tumor stage. The study also verified that the NLR and PLR are simple laboratory parameters that can be used to identify NETs with worse outcomes \[[@b32-medscimonit-23-5574]\]. Yucel et al. investigated 52 patients with NETs and demonstrated the prognostic importance of the NLR in their study \[[@b33-medscimonit-23-5574]\]. Regarding gastric NET, blood NLRs can also be an independent prognostic factor for RFS and OS \[[@b19-medscimonit-23-5574]\]. In the present study, we found that the NLR and PLR were significantly higher in patients with PNETs than in matched NVs. Furthermore, the NLR, but not the PLR, is an independent prognostic factor associated with both OS and DFS in patients with PNET. In addition, we found that a preoperative NLR \>2.31 was predictive of significantly worse survival in the subgroup of patients with stage I/II or grade 1/2 tumors. Thus, the preoperative NLR may be able to predict a poor prognosis in patients with stage I/II or grade 1/2 tumors. However, the prognostic value of the PLR was limited in our study. Patients with a low PLR at diagnosis showed significantly prolonged OS and DFS compared to patients with a high PLR in the univariate analysis; however, PLR did not show prognostic significance in the multivariate analysis. Nevertheless, given the large number of patients enrolled in this study and the effect of the NLR on prognosis in PNET demonstrated herein, our study is an important addition to the relevant literature on this topic.

The cut-off values for the NLR and PLR were important in our analysis. The cut-off value for NLR that is commonly used many studies is 5.0 \[[@b30-medscimonit-23-5574],[@b31-medscimonit-23-5574],[@b33-medscimonit-23-5574],[@b34-medscimonit-23-5574]\], while PLR cut-off values varying from 150 to 300 have been used in other studies \[[@b29-medscimonit-23-5574]--[@b32-medscimonit-23-5574]\]. In most of the above studies, the cut-off values for the NLR and PLR were set empirically. In contrast to those studies \[[@b31-medscimonit-23-5574],[@b33-medscimonit-23-5574]\], our study used cut-off values for NLR and PLR that were calculated with an ROC curve based on survival predictions. Our results demonstrated that the best cut-off values for the NLR and PLR were 2.31 and 151.4, with AUCs of 0.785 and 0.67, respectively, indicating that the NLR was superior to the PLR as a predictive factor in patients with PNET undergoing potentially curative resection.

Although the biology underlying the abovementioned increases in the NLR and PLR remains unclear, it is widely accepted that tumor development is associated with inflammation and immunity. Inflammation plays an important role in tumor growth \[[@b35-medscimonit-23-5574]--[@b37-medscimonit-23-5574]\]. Inflammatory mediators and cytokines, such as epidermal growth factor (EGF), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), fibroblast growth factors (FGFs), and interleukins (IL-4, IL-8, IL-10 and IL-13), which are produced by the tumor or as part of the host innate immune response, can promote angiogenesis, cause matrix degradation and cancer progression, and facilitate immunosuppression \[[@b38-medscimonit-23-5574],[@b39-medscimonit-23-5574]\]. All of the above pathways converge to activate transcription factors, such as NF-kappaB and STAT3, leading to downstream recruitment of inflammatory mediators and leukocytes in the tumor environment \[[@b40-medscimonit-23-5574]\]. This microenvironment also potentiates and enhances the neoplastic risk and ultimately promotes metastatic spread. Research has confirmed the existence of a relationship between the inflammatory microenvironments of tumors and the systemic responses induced by tumors. A variety of prognostic markers associated with the presence of a systemic inflammatory response have been described in a previous study \[[@b41-medscimonit-23-5574]\].

In recent years, WHO classification, TNM stage, distant metastases, surgical margin status, tumor sizes, and Ki-67 indices have been suggested as valuable prognostic factors in patients with PNETs \[[@b8-medscimonit-23-5574]--[@b11-medscimonit-23-5574]\]. To the best of our knowledge, the existing stratification systems and predictive models for PNET, including the abovementioned TNM staging system, WHO classification and 2 nomograms \[[@b42-medscimonit-23-5574],[@b43-medscimonit-23-5574]\], lack indicators of systemic inflammation, which could offer additional information for prognostic evaluation. Herein, we incorporated the NLR into the AJCC stage and WHO classification and showed that the predictive ability of models integrating the NLR and the stratification systems for OS was superior to that of the stratification systems alone. The results support the integration of the NLR into the conventional stratification systems for an improved discriminative ability.

Our study had several limitations that must be considered. First, given its retrospective design, the current study was subject to possible selection bias and diagnostic bias. Second, the NLR, a marker of systemic inflammation, may be affected by many conditions, including chemotherapy toxicity, chronic inflammatory diseases, granulocyte colony-stimulating factor administration, pathogenic inflammation, and other diseases. Therefore, these conditions must be accounted for in clinical practice. Moreover, the present study was conducted at a single institution. The performance of multicentre studies of the markers used herein would strengthen our conclusions. Finally, only patients who underwent surgery were included in the study, and it does not cover most of the advanced cases; thus, our results may not apply to patients without indications for surgical resection due to advanced stage.

Conclusions
===========

As an easily accessible inflammation-based biomarker, the preoperative NLR, but not the PLR, was an independent predictor of OS and DFS in patients who underwent potentially curative resection for PNETs. Furthermore, we confirmed that prognostic models incorporating the NLR into the TNM staging system or WHO classification provided improved predictive accuracy compared with those incorporating the stratification systems alone. Therefore, we recommend that surgeons develop a treatment plan that considers not only the TNM stage but also these prognosis-related serum biomarkers in order to improve personalized therapy for patients with PNETs.
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![Kaplan-Meier survival curves for the different PNET subgroups. An NLR \>2.31 was significantly correlated with shorter OS in older (\>56 years) (**A**) patients with low-grade tumors (grade 1/2) (**B**), patients with tumors without perineural invasion (**C**), and patients with tumors without LVSI (**D**).](medscimonit-23-5574-g004){#f4-medscimonit-23-5574}

![Kaplan-Meier survival curves for the different PNET subgroups. An NLR \>2.31 was significantly correlated with poor DFS in patients with stage I/II disease (**A**), patients with low-grade tumors (**B**), patients with tumors without perineural invasion (**C**), and patients with tumors without LVSI (**D**).](medscimonit-23-5574-g005){#f5-medscimonit-23-5574}

![ROC curve for the NLR and other predictive models in resectable PNETs. The NLR had a higher AUC value than the PLR and LMR (**A**), while the prognostic models incorporating the NLR into the TNM staging system or WHO classification provided improved predictive accuracy compared with the prognostic models of the stratification systems alone (**B**).](medscimonit-23-5574-g006){#f6-medscimonit-23-5574}

###### 

Comparison of blood cell counts between PNET patients and NVs.

  Variables                     PNET (N=172)   NVs (N=172)    p Values
  ----------------------------- -------------- -------------- ----------
  Neutrophil counts (10^9^/l)   3.60±1.58      3.08±0.80      0.003
  Platelet counts (10^9^/l)     200.69±64.93   216.75±51.32   0.039
  Lymphocyte counts (10^9^/l)   1.64±0.56      2.08±0.58      \<0.001
  NLR                           2.48±1.57      1.55±0.45      \<0.001
  PLR                           133.39±58.71   110.48±35.68   \<0.001

PNETs -- pancreatic neuroendocrine tumours; NVs -- normal volunteers; NLR -- neutrophil to lymphocyte ratio; PLR -- platelet to lymphocyte ratio.

###### 

Baseline characteristics of the PNET patients stratified by the NLR and PLR.

  Variables               NLR   PLR                      
  ----------------------- ----- ----- ------- ----- ---- ---------
  Age (years)                         0.576              0.947
   ≤56                    61    36            69    28   
   \>56                   44    31            53    22   
  Albumin (g/l)                       0.374              0.097
   ≤45                    81    45            85    41   
   \>45                   24    22            37    9    
  Grade                               0.003              0.045
   G1                     54    19            58    15   
   G2                     40    36            49    27   
   G3                     11    12            15    8    
  AJCC stage                          0.011              0.005
   I--II                  97    53            112   38   
   III--IV                8     14            10    12   
  LVSI                                0.027              0.108
   No                     86    45            97    34   
   Yes                    19    22            25    16   
  Tumour size                         0.071              0.481
   ≤3.5 cm                67    33            73    27   
   \>3.5 cm               38    34            49    23   
  Sex                                 0.068              0.802
   Female                 62    30            66    26   
   Male                   43    37            56    24   
  Tumour location                     0.139              0.048
   Head/uncinate          31    28            35    24   
   Neck                   12    6             14    4    
   Body/tail              62    33            73    22   
  Symptomatic diagnosis               0.13               0.085
   No                     40    18            46    12   
   Yes                    65    49            76    38   
  AKT (U/l)                           0.011              \<0.001
   ≤124                   97    53            113   37   
   \>124                  8     14            9     13   
  Radical resection                   0.002              0.039
   R0                     105   61            120   46   
   R1                     0     6             2     4    
  Perineural invasion                 0.038              0.070
   No                     96    54            110   40   
   Yes                    9     13            12    10   
  Function                            0.724              0.450
   No                     79    52            91    40   
   Yes                    26    15            31    10   

PNETs -- pancreatic neuroendocrine tumours; NLR -- neutrophil to lymphocyte ratio; PLR -- platelet to lymphocyte ratio; LVSI -- vascular lymph node invasion; AKT -- alkaline phosphatase.

###### 

Variables associated with OS according to the Cox proportional hazards regression model.

  Variables               Univariable analysis   Multivariable analysis                                         
  ----------------------- ---------------------- ------------------------ --------- ----------- --------------- -------
  Age (years)                                                             0.076                                 
   ≤56                    Reference                                                                             
   \>56                   2.085                  0.926--4.696                                                   
  NLR                                                                     \<0.001                               0.006
   ≤2.31                  Reference                                                 Reference                   
   \>2.31                 4.907                  2.048--11.756                      4.471       1.531--13.054   
  PLR                                                                     0.003                                 0.205
   ≤151.4                 Reference                                                 Reference                   
   \>151.4                3.307                  1.499--7.297                       NA          NA              
  LMR                                                                     \<0.001                               0.228
   ≤3.22                                                                            Reference                   
   \>3.22                 0.168                  0.067--0.425                       NA          NA              
  Albumin (g/l)                                                           0.249                                 
   ≤45                    Reference                                                                             
   \>45                   1.640                  0.707--3.804                                                   
  Grade                                                                   \<0.001                               0.001
   G1                     Reference                                                 Reference                   
   G2                     6.666                  1.491--29.805                      0.851       0.114--6.367    
   G3                     45.599                 9.676--214.977                     5.360       0.616--46.666   
  AJCC stage                                                              \<0.001                               0.004
   I--II                  Reference                                                 Reference                   
   III--IV                4.034                  2.609--6.239                       3.946       1.568--9.929    
  LVSI                                                                    \<0.001                               0.531
   No                     Reference                                                 Reference                   
   Yes                    9.777                  4.152--23.021                      NA          NA              
  Tumour size                                                             0.023                                 0.782
   ≤3.5 cm                Reference                                                 Reference                   
   \>3.5 cm               2.557                  1.135--5.760                       NA          NA              
  Sex                                                                     0.068                                 
   Female                 Reference                                                                             
   Male                   2.161                  0.945--4.941                                                   
  Tumour location                                                         0.084                                 
   Head/uncinate          Reference                                                                             
   Neck                   1.553                  0.201--11.996                                                  
   Body/tail              0.398                  0.177--0.896                                                   
  AKT (U/L)                                                               \<0.001                               0.519
   ≤124                   Reference                                                 Reference                   
   \>124                  5.442                  2.37--12.495                       NA          NA              
  Radical resection                                                       0.006                                 0.025
   R0                     Reference                                                 Reference                   
   R1                     5.566                  1.655--18.724                      5.059       1.231--20.798   
  Perineural invasion                                                     \<0.001                               0.036
   No                     Reference                                                 Reference                   
   Yes                    6.943                  3.027--15.925                      2.683       1.065--6.763    
  Function                                                                0.03                                  0.245
   No                     Reference                                                 Reference                   
   Yes                    0.109                  0.015--0.808                       NA          NA              
  Symptomatic diagnosis                                                   0.044                                 0.069
   No                     Reference                                                 Reference                   
   Yes                    3.475                  1.056--11.658                      NA          NA              

PNETs-- pancreatic neuroendocrine tumours; NLR -- neutrophil to lymphocyte ratio; PLR -- platelet to lymphocyte ratio; LMR -- lymphocyte to monocyte ratio; OS -- overall survival; LVSI -- vascular lymph node invasion; AKT -- alkaline phosphatase; NA-- not available.

###### 

Variables associated with DFS according to the Cox proportional hazards regression model.

  Variables               Univariable analysis   Multivariable analysis                                         
  ----------------------- ---------------------- ------------------------ --------- ----------- --------------- -------
  Age (years)                                                             0.087                                 
   ≤56                    Reference                                                                             
   \>56                   1.663                  0.929--2.976                                                   
  NLR                                                                     \<0.001                               0.015
   ≤2.31                  Reference                                                 Reference                   
   \>2.31                 4.143                  2.229--7.701                       2.531       1.202--5.329    
  PLR                                                                     0.001                                 0.275
  ≤151.4                  Reference                                                 Reference                   
   \>151.4                2.617                  1.465--4.675                       NA          NA              
  LMR                                                                     0.001                                 0.477
   ≤3.22                  Reference                                                 Reference                   
   \>3.22                 0.365                  0.203--0.654                       NA          NA              
  Albumin (g/l)                                                           0.426                                 
   ≤45                    Reference                                                                             
   \>45                   1.299                  0.682--2.470                                                   
  Grade                                                                   \<0.001                               0.001
   G1                     Reference                                                 Reference                   
   G2                     10.426                 3.16--34.398                       1.659       0.413--6.663    
   G3                     42.931                 12.345--149.297                    5.632       1.303--24.349   
  AJCC stage                                                              \<0.001                               0.003
   I--II                  Reference                                                             Reference       
   III--IV                4.899                  3.406--7.045                       2.771       1.423--5.397    
  LVSI                                                                    \<0.001                               0.163
   No                     Reference                                                 Reference                   
   Yes                    5.363                  2.981--9.648                       NA          NA              
  Tumour size                                                             0.001                                 0.611
   ≤3.5 cm                Reference                                                 Reference                   
   \>3.5 cm               2.812                  1.547--5.112                       NA          NA              
  Sex                                                                     0.001                                 0.105
   Female                 Reference                                                 Reference                   
   Male                   2.856                  1.54--5.297                        NA          NA              
  Tumour location                                                         0.173                                 
   Head/uncinate          Reference                                                                             
   Neck                   0.424                  0.126--1.429                                                   
   Body/tail              0.615                  0.338--1.121                                                   
  AKT (U/l)                                                               \<0.001                               0.107
   ≤124                   Reference                                                 Reference                   
   \>124                  3.7                    1.932--7.087                       NA          NA              
  Perineural invasion                                                     \<0.001                               0.036
   No                     Reference                                                 Reference                   
   Yes                    5.423                  2.884--10.197                      1.989       1.001--3.95     
  Function                                                                0.003                                 0.43
   No                     Reference                                                 Reference                   
   Yes                    0.114                  0.028--0.472                       NA          NA              
  Symptomatic diagnosis                                                   0.109                                 
   No                     Reference                                                                             
   Yes                    1.741                  0.883--3.430                                                   

PNETs -- pancreatic neuroendocrine tumours; NLR -- neutrophil to lymphocyte ratio; PLR -- platelet to lymphocyte ratio; LMR -- lymphocyte to monocyte ratio; DFS -- disease-free survival; LVSI -- vascular lymph node invasion; AKT -- alkaline phosphatase; NA -- not available.

###### 

Subgroup analysis for OS and DFS according to NLR.

  Variables             NLR         N (%)       OS               DFS                                       
  --------------------- ----------- ----------- ---------------- ------- ------- --------------- --------- --
  Age (years)                                                                                              
   ≤56                  ≤2.31       61 (62.9)   Reference                        Reference                 
  \>2.31                36 (37.1)   2.506       0.795--7.9       0.117   2.822   1.203--6.62     0.017     
   \>56                 ≤2.31       44 (58.7)   Reference                                                  
  \>2.31                31 (41.3)   24.399      3.162--188.259   0.002   6.105   2.389--15.597   \<0.001   
  Grade                                                                                                    
   G1/G2                ≤2.31       94 (63.1)   Reference                        Reference                 
  \>2.31                55 (36.9)   11.078      2.454--50.012    0.002   5.856   2.588--13.252   \<0.001   
   G3                   ≤2.31       11 (47.8)   Reference                                                  
  \>2.31                12 (52.2)   2.224       0.587--8.426     0.239   1.512   0.548--4.175    0.425     
  AJCC stage                                                                                               
   Stage I/II           ≤2.31       97 (64.7)   Reference                        Reference                 
  \>2.31                53 (35.3)   8.094       2.219--29.521    0.002   8.271   2.272--30.106   0.001     
   Stage III/IV         ≤2.31       8 (36.4)    Reference                        Reference                 
  \>2.31                14 (63.6)   2.902       1.047--8.042     0.041   1.783   0.87--3.655     0.114     
  LVSI                                                                                                     
   No                   ≤2.31       86 (65.6)   Reference                        Reference                 
  \>2.31                45 (34.4)   12.69       1.527--105.478   0.019   5.581   2.159--14.426   \<0.001   
   Yes                  ≤2.31       19 (46.3)   Reference                        Reference                 
  \>2.31                22 (53.7)   2.692       0.954--7.598     0.061   2.16    0.945--4.938    0.068     
  Tumour size                                                                                              
   ≤3.5 cm              ≤2.31       67 (67)     Reference                        Reference                 
  \>2.31                33 (33)     7.129       1.434--35.454    0.016   5.519   1.912--15.930   0.002     
   \>3.5 cm             ≤2.31       38 (52.8)   Reference                        Reference                 
  \>2.31                34 (47.2)   5.751       1.638--20.191    0.006   2.843   1.323--6.108    0.007     
  Sex                                                                                                      
   Female               ≤2.31       62 (67.4)   Reference                        Reference                 
  \>2.31                30 (32.6)   18.263      2.243--148.732   0.007   5.238   1.772--15.479   0.003     
   Male                 ≤2.31       43 (53.8)   Reference                        Reference                 
  \>2.31                37 (46.2)   3.806       1.226--11.812    0.021   2.979   1.4--6.339      0.005     
  Perineural invasion                                                                                      
   No                   ≤2.31       96 (64)     Reference                        Reference                 
  \>2.31                54 (36)     12.837      2.871--57.394    0.001   5.685   2.611--12.38    \<0.001   
   Yes                  ≤2.31       9 (40.9)    Reference                        Reference                 
  \>2.31                13 (59.1)   1.34        0.345--5.206     0.673   0.887   0.315--2.497    0.821     

NLR -- neutrophil to lymphocyte ratio; OS -- overall survival; DFS -- disease-free survival; LVSI -- vascular lymph node invasion.

###### 

Areas under the ROC curves of the conventional staging systems and inflammation-based prognostic scores for predicting OS in PNET patients undergoing potentially curative resection.

  Variables                    Area under the ROC curve (95% CI)   p Values
  ---------------------------- ----------------------------------- ----------
  Combined predictive models                                       
   AJCC stage + NLR            0.916 (0.869--0.962)                \<0.001
   WHO classification + NLR    0.857 (0.782--0.932)                \<0.001
  Staging systems                                                  
   AJCC stage                  0.846 (0.768--0.924)                \<0.001
   WHO classification          0.784 (0.694--0.874)                \<0.001
  Inflammation-based scores                                        
   NLR (≤2.31/\>2.31)          0.736 (0.636--0.835)                \<0.001
   PLR (≤151.4/\>151.4)        0.646 (0.529--0.764)                0.015
   LMR (≤3.22/\>3.22)          0.686 (0.574--0.797)                0.002

ROC -- receiver operating characteristic; OS -- overall survival; PNETs -- pancreatic neuroendocrine tumours; NLR -- neutrophil to lymphocyte ratio; PLR -- platelet to lymphocyte ratio; LMR -- lymphocyte to monocyte ratio.
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